Overview
Bromantane (chemical name: N-(2-adamantyl)-4-bromophenylamine, brand name Ladasten) is a synthetic compound developed in the 1980s at the Russian Academy of Medical Sciences. It belongs to the class of actoprotectors—agents that enhance physical performance and resistance to environmental stressors without the stimulant side effects of amphetamines or the sedation of traditional anxiolytics.
What makes bromantane pharmacologically unique is its dual mechanism: it simultaneously enhances dopaminergic neurotransmission (providing activating, motivating effects) and upregulates serotonin biosynthesis (producing anxiolytic effects). This combination of stimulation and anxiolysis is rare in pharmacology—most compounds provide one at the expense of the other. Bromantane achieves this by upregulating the gene expression of tyrosine hydroxylase (TH) and tryptophan hydroxylase (TPH), the rate-limiting enzymes in dopamine and serotonin synthesis respectively.
Bromantane was registered as a pharmaceutical in Russia in 2007 under the brand name Ladasten for the treatment of neurasthenia (a condition characterized by fatigue, irritability, and difficulty concentrating). It gained international attention in 1996 when several Russian athletes tested positive for the compound at the Atlanta Olympics, leading to its addition to WADA's prohibited substance list.
Despite its Russian approval and decades of research, bromantane has not undergone Western regulatory review and remains unavailable through conventional pharmacies outside Russia and CIS countries. This guide examines its mechanisms, evidence base, and practical considerations.
Quick facts
- Mechanism
- Actoprotector upregulating dopamine and serotonin biosynthesis enzymes
- Primary use
- Physical & Cognitive Performance with Anxiolysis
- Evidence
- moderate
- FDA
- Not approved
- Route
- Oral administration
- Typical results
- Improved physical performance and reduced anxiety within 2–5 days; sustained effects with continued use
Chemical information
Bromantane has a molecular mass of 306.24 g/mol and the formula C₁₆H₂₀BrN. It consists of an adamantane cage structure linked to a 4-bromophenylamine via a secondary amine bond. The adamantane moiety provides metabolic stability and lipophilicity (facilitating BBB penetration), while the bromophenyl group contributes to the compound's unique pharmacological profile.
How Bromantane works
Bromantane's mechanism is fundamentally different from classical stimulants or anxiolytics. Rather than directly agonizing or antagonizing neurotransmitter receptors, or blocking reuptake transporters, bromantane acts at the genomic level to increase the expression of enzymes responsible for neurotransmitter biosynthesis.
Bromantane upregulates tyrosine hydroxylase (TH) gene expression in dopaminergic neurons, increasing the enzymatic conversion of L-tyrosine to L-DOPA—the rate-limiting step in dopamine (and subsequently norepinephrine) synthesis. This results in elevated dopamine production capacity without the dopamine depletion, tolerance, or crash associated with compounds that increase dopamine release or block reuptake.
Simultaneously, bromantane upregulates tryptophan hydroxylase (TPH) expression, the rate-limiting enzyme in serotonin synthesis. This increase in serotonergic capacity produces anxiolytic effects without sedation or emotional blunting. The TPH upregulation also distinguishes bromantane from SSRIs, which increase synaptic serotonin by blocking reuptake but do not increase total serotonin production.
This biosynthesis-based mechanism explains several of bromantane's clinical advantages: no tolerance development with chronic use (because it enhances capacity rather than depleting reserves), no dependency or withdrawal (receptor sensitivity is not altered), no crash or rebound (neurotransmitter stores are enhanced, not depleted), and sustained effects that persist for days after discontinuation (enzyme levels remain elevated).
- TH gene upregulation: Increases tyrosine hydroxylase expression for enhanced dopamine synthesis capacity
- TPH upregulation: Increases tryptophan hydroxylase for enhanced serotonin production
- No receptor modulation: Does not directly agonize or antagonize neurotransmitter receptors
- No reuptake inhibition: Does not block DAT or SERT transporters
- No tolerance: Biosynthesis enhancement does not produce tolerance with chronic use
- Immunostimulatory: Enhances NK cell activity and immune function under stress
Pharmacokinetics
Pharmacokinetic data primarily from Russian regulatory studies.
| Parameter | Value | Significance |
|---|---|---|
| Bioavailability (Oral) | ~42% | Moderate oral bioavailability; food may improve absorption |
| Half-life | ~11.5 hours | Supports once or twice daily dosing |
| Tmax | 2–4 hours | Moderate absorption rate |
| BBB penetration | Yes (adamantane lipophilicity) | Readily reaches CNS targets |
| Protein binding | High (estimated >90%) | Extensive protein binding |
| Metabolism | Hepatic (CYP-mediated) | Multiple metabolites identified |
Dosing & administration
The approved dose in Russia (Ladasten) is 50–100 mg taken twice daily (100–200 mg total daily dose) for up to 28 days. The medication is taken after meals. For neurasthenia, the recommended course is 2–4 weeks, with the option to repeat after a break.
In the nootropic community, doses of 50–100 mg once daily are commonly used, often in the morning. Some users prefer a lower dose of 25–50 mg for mild anxiolysis without significant stimulation. Cycling is generally not considered necessary given the lack of tolerance, but periodic breaks are prudent.
The compound's effects typically become noticeable within 2–5 days of consistent use, with full effects developing over 1–2 weeks. The sustained nature of enzyme upregulation means effects persist for several days after discontinuation.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Bromantane has been used clinically in Russia since 2007 with a favorable safety record. Clinical trials showed adverse event rates comparable to placebo, and the compound lacks the abuse potential, tolerance, and withdrawal effects of traditional stimulants. It is classified as a non-narcotic, non-addictive medication in Russia.
Common
- • Mild dry mouth
- • Occasional mild headache
- • Slight insomnia if taken late in the day
- • Mild gastrointestinal discomfort
- • Rarely, mild allergic skin reactions
- • Generally very well-tolerated
Serious / potential risks
- • No serious adverse events reported in Russian clinical trials
- • Long-term effects beyond 1 year of use not well-studied
- • Unknown effects in populations with pre-existing dopaminergic conditions
- • Potential interactions with dopaminergic medications
- • Banned substance in competitive sports (WADA prohibited)
Drug interactions
Limited interaction data from Russian clinical studies.
| Medication | Interaction | Recommendation |
|---|---|---|
| Levodopa/Carbidopa | Both enhance dopamine synthesis; potentially additive | Use with caution; may need Parkinson's medication dose adjustment |
| MAO inhibitors | Increased dopamine production + decreased degradation | Avoid combination; hypertensive crisis risk |
| Psychostimulants (Amphetamine, Methylphenidate) | Additive dopaminergic effects | Avoid combination; excessive dopaminergic stimulation |
| SSRIs | Both enhance serotonergic function through different mechanisms | Generally compatible; monitor for serotonin-related effects |
| Alcohol | Bromantane may reduce subjective intoxication | May lead to excessive alcohol consumption; use caution |
Storage & handling
Tablets (Ladasten)
- • Store at room temperature (15–25°C)
- • Protect from moisture and direct light
- • Keep in original packaging
- • Shelf life 3 years (Russian labeling)
Powder Form
- • Store in airtight container
- • Keep at room temperature in dry conditions
- • Include desiccant packet
- • Stable for 2+ years if properly stored
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Russian pharmacies (Ladasten) | $10–$30 per month | Approved medication; affordable in Russia |
| International nootropic vendors | $30–$60 per month | Powder or capsule form; quality varies |
| Research chemical suppliers | $25–$50 per gram | Bulk powder; requires independent purity verification |
The bottom line
Bromantane is a nootropic compound with research interest in adaptogen, dopamine, cognitive enhancement. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying cognitive enhancement and neuroprotection
- • Individuals interested in adaptogen under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Iezhitsa IN, Spasov AA, Bugaeva LI.. Effects of bromantane on dopamine and serotonin synthesis. Bull Exp Biol Med (2001). doi: 10.1023/A:1017907502879 PMID: 11687849
- [2] Morozov IS, Ivanova IA, Lukicheva TA.. Actoprotector and adaptogen properties of bromantane. Exp Clin Pharmacol (Eksp Klin Farmakol) (1999). PMID: 10530692
- [3] Kudrin VS, Sergeeva SA, Krasnykh LM, et al.. Effects of bromantane on dopamine metabolism in rat striatum. Bull Exp Biol Med (1995).
- [4] Neznamov GG, Siuniakov SA, Teleshova ES, et al.. Ladasten (bromantane)—a new type of anxiolytic without sedative, myorelaxant, and anticonvulsive properties. Zh Nevrol Psikhiatr Im S S Korsakova (2007). PMID: 18379507
- [5] Oliynyk S, Oh S.. Actoprotective effect of ginseng: improving mental and physical performance. J Ginseng Res (2013). doi: 10.5142/jgr.2013.37.144 PMID: 23717166